The primary purpose of this study is to learn about how well different versions of thePfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severeCOVID-19 that requires a trip to the hospital, and overall use of healthcare resources,such as needing to go the doctor or urgent care due to illness. Pfizer is not enrollingany participants for this study. Instead, existing data from different health datasources will be used to help answer the scientific questions Pfizer is interested inlearning more about.
Not Provided
Biological: Vaccination
BNT162b2 vaccination
Inclusion Criteria:
- People with at least one year of pharmacy and medical enrollment in HealthVerity
prior to vaccine availability
- State of California or Louisiana resident for at least one year
Exclusion criteria:
- People currently pregnant,
- Individuals with discrepancies in sex and/or year of birth between HealthVerity
claims and California/Louisiana immunization registry datasets
- A diagnosis of COVID-19 in any setting ≤ 90 days prior to start of study or receipt
COVID-19 vaccine ≤ 90 days prior to start of study.
Pfizer Global Headquarters
New York 5128581, New York 5128638, United States
Pfizer CT.gov Call Center, Study Director
Pfizer